Leadership in medicine rarely comes with a manual for what happens outside the clinic. In this segment of the 

, Tiffany Mayo, MD, associate professor at the University of Alabama at Birmingham who will soon join UT Southwestern in Dallas, joined host Mona Shahriari, MD, associate clinical professor of 

 at Yale University, to discuss 2 of those unspoken challenges: protecting personal boundaries and navigating what it means to represent more than yourself.

How Women of Color in Medicine Navigate Representation Pressure

Shahriari and Mayo discussed how expectations around availability have shifted in medical education, with mentees increasingly expecting immediate responses regardless of personal or professional demands on a mentor's time. Mayo said she has learned to communicate response-time expectations clearly to trainees, recognizing that other people's sense of urgency does not have to become her own. She said failing to set these boundaries can compromise a mentor's ability to meet their own professional goals while supporting others.

Does Representation Pressure Feel Different for Women of Color in Medicine?

Shahriari asked Mayo whether pressure to conform feels heightened for women of color, given concerns about losing standing in professional spaces. Mayo said that pressure is real, since women of color in medicine often feel they represent broader communities and organizations rather than only themselves. She said she has come to view her presence in leadership spaces as an opportunity to contribute a distinct perspective rather than default to agreement, citing dermatologist Steve Daveluy, MD, whose own textured hair experience shapes how he approaches patients with similarly textured hair, as an example of how lived experience adds irreplaceable value.

How Does Authenticity Intersect With Professional Expectations?

Mayo also reflected on adapting her appearance, including straightening her hair for residency interviews, to align with perceptions of professionalism at the time. She said such adjustments do not necessarily compromise authenticity, but reflect cultural norms placed on those outside a profession's dominant group. Mayo said that while some adaptation may occur, staying true to one's core values and voice once seated at the table remains non-negotiable.

Editor’s note: Neither speaker had any relevant disclosures of note. This episode was summarized with the help of AI tools.

Want to join The Medical Sisterhood community? Click here to join our LinkedIn Group!

Shahriari M, Mayo T. The Medical Sisterhood: The Pressure of Representation, With Tiffany Mayo, MD. HCPLive. August 13, 2026. Accessed August 21, 2026. 

https://www.hcplive.com/view/medical-sisterhood-pressure-representation-tiffany-mayo-md

Videos

This segment of The Medical Sisterhood podcast highlights setting boundaries in mentorship and the pressure of representation for women of color in medicine.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Nearly 80% of young adults in a new study were classified in an early or intermediate stage of cardiovascular-kidney-metabolic (CKM) health, with excess adiposity emerging as the leading driver. The findings, published in Circulation: Population Health and Outcomes, suggest the seeds of atherosclerosis may be sown far earlier than previously appreciated.

"Even though heart attacks and strokes most often affect us in our 40s, 50s, 60s, actually the thing that is leading up to those heart attacks really starts to get rolling in our 20s," Donald Lloyd-Jones, MD, MS, said in an interview with HCPLive.

4 Out of 5 Young Adults Show Early Cardiovascular-Kidney-Metabolic Risk

Lloyd-Jones is an American Heart Association volunteer, a cardiologist at Boston Medical Center, professor of medicine at Boston University's Chobanian & Avedisian School of Medicine, director of the Framingham Center for Population and Prevention Science, and principal investigator of the Framingham Heart Study.

Why Young Adulthood Is a Blind Spot in Cardiovascular Prevention

Findings from prior research suggest traditional risk factors, including elevated cholesterol, elevated blood pressure, diabetes, and smoking, are associated with arterial damage in older adults. That damage, measurable by carotid ultrasound, is an indicator of greater risk for myocardial infarction and stroke. Previous research also shows levels of these risk factors in childhood, even within the normal range, are associated with greater plaque buildup later in life.

To address this gap in research, few studies have quantified this kind of arterial injury specifically in young adults, a period Lloyd-Jones and colleagues believe is critical to understanding who is on a fast track toward cardiovascular disease.

"Young adulthood, we think, is a time when atherosclerosis or plaques are really starting to get going," Lloyd-Jones said.

The CKM construct itself reflects this cardiovascular-kidney interconnection: stage 2 CKM is defined by the presence of either metabolic risk factors or kidney risk factors, and stage 3 by subclinical cardiovascular disease or advanced kidney disease, meaning kidney function is embedded in the staging system alongside traditional cardiometabolic measures rather than considered separately.

Investigators analyzed data from 1283 participants (mean age, 22.9 years; 54.4% women) in the Future of Families–Cardiovascular Health Among Young Adults (FF-CHAYA) study, an ancillary study of the Future of Families and Child Well-Being Study that Lloyd-Jones helps lead. The cohort included oversampling of participants from disadvantaged backgrounds, including unmarried mothers and those living below the poverty line.

Participants underwent carotid ultrasonography to assess early arterial injury and were classified using the American Heart Association's CKM staging construct, which ranges from stage 0 (no risk factors) to stage 4 (clinical cardiovascular disease); this analysis excluded stage 4, given its focus on primary prevention. Cardiovascular health was also quantified using Life's Essential 8 (LE8) scores, a composite of 8 metrics including diet, physical activity, sleep, nicotine exposure, body mass index, blood glycemia, blood lipids, and blood pressure.

Only 1 in 5 Young Adults Had Optimal Cardiovascular Health

Investigators found 20.7% of participants were classified as stage 0 CKM, with no CKM risk factors. The remaining 79.3% were classified in stage 1 or higher: 40.2% in stage 1 (excess or dysfunctional adiposity), 36.2% in stage 2 (metabolic or kidney risk factors), and 2.8% in stage 3 (subclinical cardiovascular disease or advanced kidney disease).

"Only about 20% of these young adults...seemed to be in kind of optimal health," Lloyd-Jones said. "Eighty percent of them were in stage 1 or higher cardiovascular kidney metabolic health."

More advanced CKM stage was associated with significantly lower LE8 scores, from 77.6 in stage 0 to 70.0 in stage 1, 63.8 in stage 2, and 64.4 in stage 3 (P < .001). Notably, this decline was driven by physiological measures, including body mass index, blood lipids, blood pressure, and glycemia, rather than self-reported health behaviors; scores for diet, physical activity, sleep, and nicotine exposure did not differ significantly across CKM stages.

Kidney-related measures also tracked with CKM stage. Mean estimated glomerular filtration rate declined across stages, from 117.7 mL/min/1.73 m² in stage 0 to 111.5 mL/min/1.73 m² in stage 3, and mean creatinine was highest in stage 3 (1.4 mg/dL) relative to earlier stages (0.8 mg/dL). Investigators noted that while variation in glycemia and kidney function was less pronounced than variation in adiposity, blood pressure, and lipids in this young cohort, early kidney involvement was still detectable well before clinical disease.

"That early weight gain is really a key driver of the whole process that leads people to developing either heart or kidney problems over lifetimes," Lloyd-Jones said.

Arterial Injury Was Already Detectable in Participants' Early 20s

More advanced CKM stage was also associated with significantly greater carotid intima-medial thickness (cIMT), an early marker of atherosclerosis. Compared with stage 0, mean-maximum cIMT was 0.014 mm greater in stage 1 (95% CI, 0.005-0.020), 0.020 mm greater in stage 2 (95% CI, 0.017-0.035), and 0.100 mm greater in stage 3 (95% CI, 0.085-0.128).

Although these differences are small in absolute terms, investigators noted prior research has linked even modest cIMT differences to significantly greater risk of myocardial infarction and stroke in older adults, associations they suggest may be amplified in a younger population.

What These Findings Mean for Physicians Seeing Patients in Their 20s

"In your early 20s is actually a really really important time to be connected with the healthcare system, to have a healthcare practitioner, to make plans," Lloyd-Jones said.

Lloyd-Jones noted that in most cases, risk factors identified in a patient's 20s can be addressed through lifestyle change alone, including improved eating patterns and more regular physical activity, potentially restoring health rather than simply preserving it. He said medication is rarely necessary in this age group unless risk factors are already significantly elevated, underscoring the importance of knowing key numbers, including cholesterol, blood pressure, and blood glucose trends, earlier rather than later.

"Things may already be getting started that could affect them either shortening their lifespan or really degrading their health for the long term," Lloyd-Jones said.

Krishnan V, Ning H, Notterman DA, et al. Association between cardiovascular-kidney-metabolic health and early arterial injury in young adults in the United States: the Future of Families–Cardiovascular Health Among Young Adults Study. 

. 2026;19:e013042. doi:10.1161/CIRCOUTCOMES.125.013042

Ndumele CE, Rangaswami J, Chow SL, et al; American Heart Association. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. 

. 2023;148:1606-1635. doi:10.1161/CIR.0000000000001184

Carotid ultrasound data reveal early arterial injury even at earlier CKM stages, says Donald Lloyd-Jones, MD, MS

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Manish Wadhwa, MD, is a cardiologist and electrophysiologist with San Diego Arrhythmia Associates and the chief executive officer of SummaCor.

 granted 510(k) clearance to the ILR ECG Analyzer, which serves as a second layer for residual alerts generated by implantable cardiac monitors (ICMs).

FDA-Cleared, AI-Assisted ECG Analyzer Algorithm Reduces False Positives in ICMs

ICMs are well-known for their tendency to produce false positive alerts, detecting 

 that are not present or clinically significant. Even with the implementation of AI algorithms to filter these alerts from genuine arrhythmias, the substantial burden posed by false positives still lingers. Past research has shown that many devices register benign rhythms or certain signal artifacts, such as electrical noise or premature ventricular contractions, which are frequently labeled as significant events.

To combat this, Implicity’s ILR ECG Analyzer was developed to act as a backup filter for alerts that bypass initial manufacturer filters. The algorithm can analyze data from all major device manufacturers. Recent research has shown that the algorithm reduced false positives by ≤76% while maintaining high sensitivity for detecting clinically meaningful events.

“Essentially, you keep looking at something – if it’s real, that’s great, but you get so much information that’s not real that it creates a major workflow challenge,” Manish Wadhwa, MD, a cardiologist and electrophysiologist with San Diego Arrhythmia Associates and chief executive officer of SummaCor, told 

 in an exclusive interview. “That’s why something like this, this AI-based analyzer, is so important: it helps to mitigate the workflow challenges.”

, investigators conducted a multicenter, multivendor database analysis of ICMs to compare the accuracy of arrhythmia detection between 4 commonly used ICMs – the LINQ II from Medtronic (MDT), the LUX-Dx from Boston Scientific (BSX), the Biomonitor III from Biotronik (BIO), and the Confirm Rx from Abbott (ABT). A total of 437,351 electrocardiogram-verified episodes were collected from 6756 patients across 25 centers – investigators selected a random sample of 1140 patients based on a prospectively determined power analysis.

The study cohort generated 25,826 total alerts, with a median of 5 alerts (interquartile range [IQR], 2-14) per patient. ICM implant indications included cryptogenic stroke (21%), suspected atrial fibrillation (11.3%), atrial fibrillation management (23.6%), syncope (23.2%), palpitations (14.9%), ventricular tachycardia (2.1%), and unknown (3.8%).

Atrial tachycardia and atrial fibrillation were the most frequent alerts (BIO, 70.8%; MDT, 68%; ABT, 55.7%; BSX, 35.7%). After adjudication, BSX displayed the highest positive predictive values, followed by ABT and MDT, while BIO had the lowest (BSX, 0.73; MDT, 0.56; ABT, 0.51; BIO, 0.23). False positives for atrial tachycardia and atrial fibrillation were attributed to ectopy (75.8%), combined ectopy with oversensing or noise (5.3%), isolated oversensing (5.2%), sinus arrhythmias (3.9%), indeterminate reason (3.7%), noise (3.6%), and bradycardia (2.5%).

BSX demonstrated the highest positive prediction values (0.96), while MDT had the lowest (0.36) – this was primarily attributed to undersensing. ABT had the lowest pause detection accuracy (positive prediction values: 0.01; 79.8% due to undersensing) and BSX had the highest (positive prediction values: 0.7). Additionally, tachycardia alerts had moderate positive prediction values for BIO (0.62) and BSX (0.61), with substantially lower values for MDT (0.29) and ABT (0.27).

“There is one other benefit to this as well, and that is standardization. If you took a single strip and you asked 20 different practitioners to interpret that strip, sadly, you’re probably going to get about 10 to 15 different answers,” Wadhwa said. “To that end, if there is a ground truth, what you actually want is for the standardized output to be the truth. You can keep asking people and you’ll keep coming back with different answers, but the AI is very sure, and if we train the models properly, it will always come back the same way.”

Editors’ Note: Wadhwa reports no relevant disclosures.

Implicity. Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance. 

. July 28, 2026. Accessed August 21, 2026. 

https://www.globenewswire.com/news-release/2026/07/28/3334149/0/en/implicity-s-next-generation-ilr-ecg-analyzer-earns-fda-clearance.html

Implicity. EHRA 2026 Studies Reveal Why False Positives Persist in AI-Equipped Implantable Cardiac Monitors. April 14, 2026. Accessed August 21, 2026. 

https://implicity.com/ehra-2026-studies-reveal-why-false-positives-persist-in-ai-equipped-implantable-cardiac-monitors/

Kamsani SH, Middeldorp ME, Evans S, et al. Accuracy of implantable loop recorders. JACC: Clinical Electrophysiology. 2026;12(5):1113-1127. 

Manish Wadhwa, MD, discusses Implicity’s newest algorithm to improve the accuracy of implantable cardiac monitors in identifying arrhythmic episodes.

Arrhythmia

FDA News

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Pamufetinib (TAS-115), an oral multikinase inhibitor, failed to slow FVC decline compared with continued nintedanib or pirfenidone in a phase 2b trial of patients with progressive 

chronic fibrosing interstitial lung disease (CF-ILD).

“The FVC decline in the pamufetinib 100 mg group was suppressed until week 10, which was consistent with the previous phase 2a study,” wrote investigator Ryo Okuda, from Kanagawa Cardiovascular and Respiratory Center in Japan, and colleagues.

 “However, after week 16, the rate of FVC decline was reversed, resulting in an FVC that was lower in the pamufetinib 100 mg group than the control group.”

No therapy is currently recommended for CF-ILD with disease progression despite treatment with nintedanib or pirfenidone. The earlier phase 2a single-arm study of pamufetinib suggested a delay in disease progression among patients with FVC decline on standard antifibrotic therapy, using intrapatient slope change as a surrogate endpoint.² This phase 2b study tested whether the signal would translate into a dose-dependent benefit when pamufetinib replaced standard antifibrotic therapy outright.

Pamufetinib Efficacy in the Phase 2b Chronic Fibrosing ILD Trial

This double-blind, multicenter, active-controlled phase 2b trial enrolled patients at 41 sites in Japan between October 2021 and June 2024.¹ Eligible patients had CF-ILD with a progressive phenotype, defined as a relative %FVC decline of ≥ 5% per year despite nintedanib or pirfenidone, and an %FVC of ≥ 50%. Patients were randomized 1:1:1 to pamufetinib 100 mg, pamufetinib 50 mg, or control therapy consisting of continued nintedanib or pirfenidone, using a double-dummy design to preserve blinding across the differing dosage forms.

Pamufetinib was administered on a 5-day-on/2-day-off oral schedule for 26 weeks. Of 243 patients randomized and treated, 71.0% had IPF, and mean %FVC was approximately 74% across the 3 arms.

The primary endpoint, 26-week rate of decline in FVC, was -157.8 mL (95% CI, -208.8 to -106.9) with pamufetinib 100 mg, -96.0 mL (95% CI, -145.4 to -46.6) with pamufetinib 50 mg, and -63.6 mL (95% CI, -111.8 to -15.5) with control therapy. No dose-response relationship was observed, and the 100 mg arm showed a numerically greater decline than control. Investigators noted the 100 mg arm maintained early suppression of FVC decline through week 10 before the effect reversed between weeks 16 and 26.

Pamufetinib Safety Profile and Secondary Endpoints in CF-ILD

Pamufetinib 50 mg and 100 mg failed to slow 26-week FVC decline versus continued nintedanib or pirfenidone in 243 patients with progressive CF-ILD (-96.0 mL and -157.8 mL vs -63.6 mL with control).

No dose-response relationship was observed, and the 100 mg dose showed numerically greater FVC decline and more acute exacerbations than control.

Switching from standard antifibrotic monotherapy to pamufetinib provided no benefit, leaving nintedanib and pirfenidone the only approved options for CF-ILD.

Absolute change in %DLco from baseline at 26 weeks was -5.2% with pamufetinib 100 mg, -3.4% with pamufetinib 50 mg, and -2.6% with control therapy.¹ Acute exacerbation occurred in 12.8% (10/78) of the pamufetinib 100 mg group, 9.6% (8/83) of the pamufetinib 50 mg group, and 3.8% (3/80) of the control group by week 26. Death occurred in 3.8%, 6.0%, and 2.5% of patients, respectively, though the 26-week trial was not designed to detect survival differences.

Rash was the most frequent adverse event in both pamufetinib arms, reported in 29.1% of the 100 mg group and 14.3% of the 50 mg group versus 10.0% of the control group. Most cases were mild to moderate in severity.

Adverse events coded as ILD, encompassing both acute exacerbations and newly diagnosed disease, occurred in 10.1% of the 100 mg group, 9.5% of the 50 mg group, and 3.8% of the control group. The study reported serious adverse events in 27.8%, 20.2%, and 15.0% of patients across the same groups. Treatment discontinuation occurred in 12.7% and 11.9% of the pamufetinib 100 mg and 50 mg groups, respectively, compared with no discontinuations in the control group.

Investigators attributed the unfavorable FVC trajectory partly to pamufetinib's off-target inhibition of MET, AXL, and Src alongside its intended PDGFR, VEGFR, and CSF1R targets, since MET signaling supports alveolar epithelial repair after lung injury.³ Subgroup analyses stratified by IPF status and prior antifibrotic treatment showed results consistent with the overall population, with no benefit favoring pamufetinib.¹

The findings indicate no advantage to switching from standard antifibrotic monotherapy to pamufetinib in patients progressing despite treatment, leaving nintedanib and pirfenidone the only approved options for CF-ILD.

Okuda R, Nishioka Y, Kondoh Y, et al. Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial. 

Nishioka Y, Homma S, Ogura T, et al. Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis. 

Articles

Pamufetinib (TAS-115), an oral multikinase inhibitor, did not improve physiologic outcomes when substituted for nintedanib or pirfenidone in progressive chronic fibrosing ILD. In a double-blind, active-controlled phase 2b Japanese study, FVC decline at 26 weeks was numerically worse with pamufetinib 100 mg and not dose-responsive versus control therapy. Early FVC suppression through week 10 in the 100 mg arm reversed after week 16. Safety signals included higher rash rates, more acute exacerbations, and greater discontinuations.

Pamufetinib 50 mg and 100 mg did not slow FVC decline versus continued nintedanib or pirfenidone in progressive fibrosing ILD, a phase 2b trial found.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Pamufetinib Fails to Slow FVC Decline in Progressive Fibrosing ILD

Part 2 of the phase 3 ABTECT maintenance trial found that obefazimod sustained clinical remission through week 44 in

patients, including those who had not initially responded to induction therapy. The results build on positive Part 1 data and add to a growing safety database ahead of the company's planned 

"These results that we'll probably be talking about today are really building upon very impressive induction data, where we saw placebo-adjusted treatment differences for the primary endpoint of clinical remission, which was quite substantial," Remo Panaccione, MD, professor of medicine and director of the IBD Clinic at the University of Calgary, said in an interview with HCPLive.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD

How Large Was the ABTECT Maintenance Population?

Panaccione noted the onset of benefit was rapid, "with separation from placebo as early as one week for symptomatic response and week two for symptomatic remission." Part 1 of the maintenance study enrolled 580 patients who had responded to induction and entered the randomized, placebo-controlled maintenance phase, while Part 2 added 633 patients who had either not responded during induction or lost response during maintenance.

"This study also included a substantial portion of patients who were difficult to treat," Panaccione said. "In particular, it enrolled the largest cohort of patients with an inadequate response to a JAK inhibitor that we've ever studied in phase three clinical trials." He noted JAK inhibitor exposure typically signals later-line therapy, where patients tend to respond less robustly than treatment-naive patients or those exposed only to monoclonal antibodies.

Both the 25 mg and 50 mg doses met the primary endpoint of clinical remission at week 44, with remission rates around 51% compared to 10% with placebo. "This 40% difference, which is the largest placebo-adjusted difference that we've seen in a phase three trial, part of that may have been due to the fact that the placebo rate was quite low, and that speaks usually to the difficult-to-treat patient population," Panaccione said. Among initial non-responders continued on 50 mg, approximately 37% achieved remission and >60% achieved response; among those who relapsed on 25 mg and were escalated to 50 mg, remission was recaptured in approximately 56%.

What Did Endoscopic Remission Rates Show?

For Panaccione, the endoscopic data carried particular weight. "To get into the trial, the patients needed a Mayo endoscopy score of either two or three, signaling moderate to severe endoscopic disease. To achieve endoscopic remission, you needed to go all the way from that down to an endoscopic score of zero," he said. "This is important because this is a highly objective measure of drug efficacy."

Endoscopic remission was achieved in 41.5% of patients on 25 mg and 47.7% on 50 mg, compared to 10% with placebo. "These are amongst the highest endoscopic remission rates that we've seen, and this strong endoscopic remission data really signifies or signals the potential of this drug in moderate to severe ulcerative colitis," Panaccione said. Both doses also met key secondary endpoints, including endoscopic improvement, histologic-endoscopic mucosal improvement, and steroid-free remission, with no concerning safety signals through 44 weeks.

Is Obefazimod's Safety Profile Holding Up With Longer Exposure?

Addressing the drug's safety profile, Panaccione cautioned against over-reading early signals. "When the induction data was first released publicly, there were a few malignancies in the 50 mg dose, and I think that was a little bit misinterpreted," he said. "When we're interpreting rare safety events such as malignancy, it's important not to focus solely on the raw numbers... simple case counts can be really misleading, particularly when the amount of treatment exposure differs amongst groups."

He explained that the 50 mg group had both the greatest cumulative exposure and the most treatment-refractory patients, which would naturally be expected to produce more events. "The important thing is to look at exposure-adjusted incidence rates, and that's a more appropriate way to look at safety in general," Panaccione said.

Across the phase 2 and phase 3 programs, exposure totaled >1,700 patient-years. Rates of non-melanocytic skin cancer were consistent with published malignancy rates in UC, Panaccione said, noting that a prostate cancer and a breast cancer observed in the 50 mg group were not rare cancers and occurred in patients where they would be expected. "Certainly, the available data doesn't suggest a dose-dependent malignancy signal with obefazimod," he said. With phase 2 data now extending beyond four years, Panaccione characterized the overall benefit-risk profile as favorable.

Editors' note: Panaccione has relevant disclosures with Abbott, AbbVie, Abivax, Alimentiv, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Ferring, Galapagos, Gilead Sciences, Janssen, Merck, Novartis, Pfizer, Takeda, and others.

Abivax announces landmark Phase 3 ABTECT maintenance trial results evaluating obefazimod in moderately to severely active ulcerative colitis. News release. Abivax. June 1, 2026. Accessed August 19, 2026. 

https://www.globenewswire.com/news-release/2026/06/01/3304711/0/en/abivax-announces-landmark-phase-3-abtect-maintenance-trial-results-evaluating-obefazimod-in-moderately-to-severely-active-ulcerative-colitis.html

Abivax reports positive ABTECT maintenance Part 2 results for obefazimod, demonstrating meaningful clinical benefit in refractory ulcerative colitis patients and strengthening the Phase 3 maintenance safety database. News release. Abivax. June 29, 2026. Accessed August 19, 2026. 

https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results/

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Melinda Gooderham, MD, is a dermatologist and the medical director at the SKiN Centre for Dermatology.

This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.

Alopecia

Q&A: Upadacitinib Drives Eyebrow, Eyelash Regrowth with Consistent Safety

Andrew Mastro, MS, PA-C, closes out this stretch of the conversation by asking Alexa Hetzel, MS, PA-C, to look three to five years ahead and describe how she expects the plaque psoriasis treatment paradigm to evolve.

The Future of Plaque Psoriasis Treatment Over the Next 3 to 5 Years

Andrew Mastro, MS, PA-C, widens the lens and asks Alexa Hetzel, MS, PA-C, where icotrokinra sits within the broader plaque psoriasis landscape, including whether route of administration itself shapes patient preference.

Positioning Icotrokinra as First-Line Therapy for Plaque Psoriasis

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

PAH specialists discuss upfront combination therapy and the disconnect between guidelines and community practice.

PAH in Community Practice: Algorithms and Access

Genetic variants tied to CAR T toxicity and expansion could guide how researchers screen healthy donors for allogeneic CAR T products.

Hematology

Selecting Donor T Cells for CAR T Therapy, With Mark B. Leick, MD

This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.

Q&A: Upadacitinib Meets Primary Endpoint in Severe Alopecia Areata Trials

Nathaniel Lebowitz, MD, is an attending cardiologist at the Hackensack University School of Medicine and an assistant professor of internal medicine at the Hackensack Meridian School of Medicine.

Lp(a) is one of the biggest contributors to cardiovascular disease, but recent studies have shown that awareness of and testing for the condition is subpar nationwide.

Dyslipidemia

Atherosclerotic Cardiovascular Disease

AHA Publishes Results of Nationwide Initiative for Lp(a) Education and Awareness

Deupirfenidone 825 mg reduced 26-week FVC decline by 91.0 mL versus placebo in the phase 2b ELEVATE-IPF trial in idiopathic pulmonary fibrosis.

Deupirfenidone Slows FVC Decline in Phase 2b IPF Trial

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

A recent secondary analysis of the HELIOS-B trial has highlighted vutrisiran’s effects on atrial myopathy in patients with ATTR-CM.

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Left Atrial Strain Indicates Worse ATTR-CM Prognosis, but Attenuable With Vutrisiran

The generic nasal spray is bioequivalent to Haleon's Flonase, indicated for nasal symptoms of allergic rhinitis.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Latest News

How Women of Color in Medicine Navigate Representation Pressure

4 Out of 5 Young Adults Show Early Cardiovascular-Kidney-Metabolic Risk

FDA-Cleared, AI-Assisted ECG Analyzer Algorithm Reduces False Positives in ICMs

Pamufetinib Fails to Slow FVC Decline in Progressive Fibrosing ILD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD